SCHEMBL10242473

SCHEMBL10242473

CC1CCN(C(N)=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20331851 1.00
SCHEMBL13841231 1.00
SCHEMBL3314468 0.87 ALDH1A1 (0.59)
SCHEMBL3588954 0.87 ALDH1A1 (0.59)
SCHEMBL1336653 0.86 ALDH1A1 (0.54)
SCHEMBL14626911 0.83 ALDH1A1 (0.42)
SCHEMBL27889775 0.81 ALDH1A1 (0.48)
SCHEMBL13634298 0.80
SCHEMBL14708495 0.80 PDE4B (0.35)
SCHEMBL6037523 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US claimed
WO-2025215579-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2025-10-16 WO disclosed
US-20250243194-A1 ANTAGONIST OF ADENOSINE RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2025-07-31 US disclosed
US-20230293517-A1 ANTAGONIST COMPOUNDS JANSSEN PHARMCEUTICA NV (BE) 2023-09-21 US disclosed
US-10030019-B2 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors FEDORA PHARMACEUTICALS INC. (CA) 2018-07-24 US disclosed
EP-2863916-B1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME (US) 2018-07-18 EP disclosed
WO-2018020004-A1 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS ABAC THERAPEUTICS, S.L (ES) 2018-02-01 WO disclosed
US-9751873-B2 Aryl sultam derivatives as RORc modulators GENENTECH, INC. (US) 2017-09-05 US disclosed
US-9393239-B2 Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors FEDORA PHARMACEUTICALS INC. (CA) 2016-07-19 US disclosed
US-20160168141-A1 ARYL SULTAM DERIVATIVES AS RORc MODULATORS GENENTECH, INC. (US) 2016-06-16 US disclosed
US-9115101-B2 Aryl sultam derivatives as RORc modulators GENENTECH, INC. (US) 2015-08-25 US disclosed
US-20150197529-A1 ARYL SULTAM DERIVATIVES AS RORc MODULATORS GENENTECH, INC. (US) 2015-07-16 US disclosed
US-20140221341-A1 BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETALACTAMASE INHIBITORS NAEJA PHARMACEUTICAL INC. (CA) 2014-08-07 US disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US disclosed
US-20140031330-A1 ARYL SULTAM DERIVATIVES AS RORc MODULATORS GENENTECH INC (US) 2014-01-30 US disclosed
WO-2013043826-A1 TRICYCLIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS ABBVIE INC. (US) 2013-03-28 WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 US disclosed
WO-2012085167-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-06-28 WO disclosed